Journal of psychoactive drugs
July 2, 2025
Brian S Barnett, Miranda Arakelian, Jeremy Weleff et al.
2 citations
In 2023, a survey of 109 U.S. psychiatry residents found that most had limited formal education on psychedelics during training but strongly desired more instruction. 83.49% believed psychedelics hold promise for psychiatric disorders, though fewer (55.96%) saw similar potential for substance use disorders. Nearly 40% reported that psychedelic-related educational or research opportunities influenced their residency program rankings, and a similar proportion said the possibility of treating patients with psychedelics influenced their decision to pursue psychiatry. Higher knowledge scores and stronger belief in therapeutic potential were linked to greater influence on program ranking. The findings suggest a need to expand psychedelic-focused education in residency.
Psychedelic Medicine
December 30, 2025
Brian S. Barnett, Akhil Anand, Tatiana Falcone et al.
Between 2015 and 2019, past-year LSD use rose 43% among heterosexual individuals, 58% among bisexual individuals, and 106% among lesbian/gay individuals in the United States. Lesbian, gay, and bisexual (LGB) people were 3.3 to 4.4 times more likely to report past-year LSD use than heterosexual people, depending on the year. Living in poverty, being divorced versus married, living in a small metropolitan area versus a non-metropolitan area, and a past-year suicide attempt were unique correlates of LSD use for heterosexual individuals compared with LGB individuals. The findings suggest a need for targeted harm reduction strategies based on sexual identity.
Contemporary clinical trials
February 1, 2025
Noreen A Reilly-Harrington, Tatiana Falcone, David A Jobes et al.
A randomized controlled trial is testing whether ketamine infusions, compared to placebo, rapidly reduce severe suicidality in youth and young adults (ages 14-30) hospitalized with suicidal ideation or after a suicide attempt. Participants receive up to six treatments of ketamine or placebo while also engaging in Collaborative Assessment and Management of Suicidality (CAMS) sessions, a suicide-focused therapy, starting in the hospital and continuing after discharge. The study enrolls 140 participants and follows them for three months. The hypothesis is that ketamine will produce faster improvement in suicidality, enhance engagement in CAMS, and reduce suicide attempts, emergency visits, and readmissions compared to placebo.